CookieStocks

Johnson & Johnson (JNJ): financials, SEC filings and peers

Johnson & Johnson (JNJ) is a pharmaceuticals company in the Health Care sector of the S&P 500, headquartered in New Brunswick, New Jersey.

It was founded in 1886 and joined the S&P 500 on June 30, 1973.

Its fiscal year ends in January, and its shares trade on the NYSE.

In its SEC filings it is classified as “Pharmaceutical Preparations”.

Johnson & Johnson at a glance

Revenue (12 months)
$99.3B
Revenue growth
+7.8%
Operating margin
18.8%
Net income (12 months)
$16.1B
Free cash flow (12 months)
$20.6B
Cash
$16.9B
Debt
$44.7B
Diluted EPS (12 months)
$6.59

Twelve months to September 27, 2026, from the 10-Q filed October 21, 2026.

Latest twelve months

Over the twelve months to September 27, 2026, Johnson & Johnson reported revenue of $99.3 billion, about the same as a year earlier (+7.8%).

Its operating margin was 18.8%, down 16.3 percentage points from a year earlier: for every $100 of sales, about $19 was left as operating profit.

Net income was $16.1 billion (16.2% of revenue), 35.9% lower than a year earlier.

Profit fell while sales grew, which usually points to higher costs, heavier investment or one-time items. The filings explain which.

Operating cash flow was $26.2 billion and capital spending $5.6 billion, leaving free cash flow of $20.6 billion (20.7% of revenue).

At the end of the period it held $16.9 billion in cash and $44.7 billion in debt, a net debt position of $27.7 billion.

Five-year trend

  • Revenue went from $82.6 billion in fiscal 2021 to $94.2 billion in fiscal 2025, about 2.7% a year.
  • Revenue has grown for 4 fiscal years in a row.
  • Free cash flow was positive in each of the last 6 fiscal years.
Fiscal year20222023202320242025
Revenue$78.7B$80.0B$85.2B$88.8B$94.2B
Revenue growth-4.7%1.6%6.5%4.3%6.0%
Operating margin—————
Net income$20.9B$17.9B$35.2B$14.1B$26.8B
Free cash flow$19.8B$17.2B$18.2B$19.8B$19.7B
Diluted EPS$7.81$6.73$13.72$5.79$11.03

Fiscal years as reported in Johnson & Johnson’s 10-K filings. Free cash flow is operating cash flow minus capital spending.

Recent SEC filings

  • 10-Q filed October 21, 2026 — quarterly report
  • 8-K filed October 13, 2026 — Earnings results
  • 8-K filed August 4, 2026 — Executive or director change
  • 8-K filed July 29, 2026 — Regulation FD disclosure
  • 8-K filed July 28, 2026 — Regulation FD disclosure
  • 10-Q filed July 23, 2026 — quarterly report
  • 8-K filed July 15, 2026 — Earnings results
  • 8-K filed April 28, 2026 — Shareholder vote results

All Johnson & Johnson filings on SEC EDGAR

Companies like Johnson & Johnson

Other S&P 500 companies in Pharmaceuticals:

More from Health Care

All 60 Health Care companies →

Questions about Johnson & Johnson

Is Johnson & Johnson's revenue growing?

Yes. Revenue for the twelve months to September 27, 2026 was $99.3 billion, up 7.8% from a year earlier, according to its SEC filings.

Is Johnson & Johnson profitable?

Yes. It earned $16.1 billion in net income over the twelve months to September 27, 2026, a net margin of 16.2%.

Does Johnson & Johnson have more cash or more debt?

At September 27, 2026 it had $16.9 billion in cash and $44.7 billion in debt, so more debt than cash.

When did Johnson & Johnson last file financial results?

Its latest quarterly report (10-Q) was filed with the SEC on October 21, 2026.

Which companies are similar to Johnson & Johnson?

In the S&P 500, Johnson & Johnson is grouped in Pharmaceuticals within the Health Care sector. Bristol Myers Squibb (BMY), Lilly (Eli) (LLY), Merck & Co. (MRK), Pfizer (PFE), Viatris (VTRS) are in the same group.

Understand the numbers

Source: Johnson & Johnson’s filings with the U.S. Securities and Exchange Commission (EDGAR), retrieved November 11, 2026. Figures are as reported by the company and may be restated. This page is for information only and is not financial advice.